Literature DB >> 19496692

Treatment of narcolepsy.

Giuseppe Didato1, Lino Nobili.   

Abstract

Narcolepsy is a neurological disorder characterized, in its classical form, by excessive daytime sleepiness (EDS) with irresistible episodes of sleep, cataplexy, disrupted nocturnal sleep, hypnagogic/hypnopompic hallucinations and sleep paralysis. It is often under-diagnosed, however, if it is suitably diagnosed, symptoms can be well treated by means of targeted drugs, such as modafinil to treat EDS, sodium oxybate for cataplexy, as well as EDS and disrupted nocturnal sleep, and tricyclic and newer antidepressants for cataplexy. Hallucinations and sleep paralysis can be treated with the same drugs used for cataplexy. Amphetamines and amphetamine-like stimulants are used less nowadays. Behavioral measures are also important and useful. The discovery of hypocretin deficiency in narcoleptic patients opens new perspectives for the development of newer therapeutic approaches for both EDS and cataplexy. Therapy for narcolepsy is chronic, hence symptomatic. However, the correct use of available drugs enables patients to gain a better quality of life, keeping the symptoms under control, which, mainly from a social point of view, are heavily disabling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496692     DOI: 10.1586/ern.09.29

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  6 in total

Review 1.  Disrupted nighttime sleep in narcolepsy.

Authors:  Thomas Roth; Yves Dauvilliers; Emmanuel Mignot; Jacques Montplaisir; Josh Paul; Todd Swick; Phyllis Zee
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

2.  Wake-promoting agent modafinil worsened attentional performance following REM sleep deprivation in a young-adult rat model of 5-choice serial reaction time task.

Authors:  Yia-Ping Liu; Che-Se Tung; Yu-Lung Lin; Chia-Hsin Chuang
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

3.  Increased lucid dreaming frequency in narcolepsy.

Authors:  Michael Rak; Pierre Beitinger; Axel Steiger; Michael Schredl; Martin Dresler
Journal:  Sleep       Date:  2015-05-01       Impact factor: 5.849

4.  Changes in the Cholinergic, Catecholaminergic, Orexinergic and Serotonergic Structures Forming Part of the Sleep Systems of Adult Mice Exposed to Intrauterine Alcohol.

Authors:  Oladiran I Olateju; Adhil Bhagwandin; Amadi O Ihunwo; Paul R Manger
Journal:  Front Neuroanat       Date:  2017-11-27       Impact factor: 3.856

5.  Effects of Modafinil on Behavioral Learning and Hippocampal Synaptic Transmission in Rats.

Authors:  Wen-Wen Yan; Li-Hua Yao; Chong Chen; Hai-Xia Wang; Chu-Hua Li; Jun-Ni Huang; Peng Xiao; Cheng-Yi Liu
Journal:  Int Neurourol J       Date:  2015-12-28       Impact factor: 2.835

Review 6.  Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation.

Authors:  Natalie Nevárez; Luis de Lecea
Journal:  F1000Res       Date:  2018-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.